Novo Nordisk AS
NOV
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
E: phak@novonordisk.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
76,302
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,913.90 | 352.20 | 4.66% |
| CAC 40 | 7,215.83 | 115.41 | 1.63% |
| DAX 40 | 20,736.06 | 1,065.18 | 5.42% |
| Dow JONES (US) | 40,608.45 | 2,962.86 | 7.87% |
| FTSE 100 | 7,985.55 | 306.07 | 3.99% |
| HKSE | 20,681.78 | 417.29 | 2.06% |
| NASDAQ | 17,124.97 | 574.37 | 3.47% |
| Nikkei 225 | 34,609.00 | 2,894.97 | 9.13% |
| NZX 50 Index | 12,201.43 | 394.88 | 3.34% |
| S&P 500 | 5,456.90 | 474.13 | 9.52% |
| S&P/ASX 200 | 7,709.60 | 334.60 | 4.54% |
| SSE Composite Index | 3,223.64 | 36.83 | 1.16% |